Marion Merrell Dow
Executive Summary
FDA accepts for filing Sabril (vigabatrin) NDA June 30 for "add-on therapy in treating patients with complex partial seizures that have not been controlled by other anti-epilepsy medications." MMD submitted the NDA May 2